Article Figures & Data
Figures
- Figure 1
- Characteristics of minor salivary gland biopsy results based on the focus score (n=24).
- Figure 2
- Frequency of extra-glandular manifestations (n=41).
Tables
Demographics n=41 Rheumatology clinic Pulmonary clinic P-value Female gender (%) 32 (78) 13 (93) 19 (70) 0.099 Age at diagnosis (years) 54.8 ± 13.4 46.9 ± 10.9 59±12.9 <0.001 Age at study inclusion (years) 58.76 ± 12.7 52.9 ± 11.9 61.8 ± 12.2 0.003 Disease duration (years) 4.6 ± 2.3 6 ± 2.5 3.9 ± 1.8 0.003 Time from symptom onset to diagnosis (years) Mean 2.2 ± 2.4 Range 1-11 Outcome measures Mean EULAR Sjogren’s Syndrome Disease Activity Index 9.95 ± 7.73 6.43 ± 9.41 11.78±6.13 0.100 Mean EULAR Sjogren’s Syndrome Patient Reported Outcome 5.17 ± 2.4 5.095 ± 2.700 5.205±2.239 0.386 Mean Patient Global Assessment 5.2 ± 2.37 4.786 ± 2.723 5.423±2.176 0.864 Mean Physician Global Assessment 4.46 ± 2.06 3.786 ± 2.455 4.815±1.777 0.879 Antibody profile; n (%) ANA 32 (78.0) 13 (93) 19 (70) 0.099 Anti-SSA 19 (46.3) 12 (86) 7 (26) <0.001 Anti-SSB 12 (29.3) 9 (64) 3 (11) <0.001 Rheumatoid factor 10 (24.4) 11 (79) 8 (30) 0.168 Presence of extra-glandular manifestations 36 (87.8) 9 (64) 27 (100) 0.001 EULAR: The European League Against Rheumatism, SSA: Sjogren’s syndrome A antibody,SSB: Sjogren’s syndrome B antibody,
Age Age at disease onset Gender ANA SSA SSB RF Lip biopsy Pulmo-nary Renal Cuta-neous Arthritis PNS Cyto-penia CNS PGA PhGA ESSDAI ESSPRI for dryness ESSPRI for fatigue ESSPRI for pain ESSPRI 18 16 Female 1 1 1 1 0 0 0 0 0 0 0 0 6 7 0 6 8 3 5.7 34 29 Female 1 0 0 1 1 1 0 0 1 0 0 0 2 2 7 1 0 1 0.7 39 32 Female 1 1 1 3 1 1 0 0 1 0 0 0 5 5 12 8 7 5 6.7 43 37 Female 1 0 0 1 1 1 0 0 1 0 0 0 5 3 7 5 5 5 5 43 40 Female 1 1 0 1 1 1 0 0 1 0 0 0 6 5 17 5 5 7 5.7 45 38 Female 1 1 1 3 3 0 1 1 0 0 1 0 2 2 14 9 3 0 4 49 42 Male 1 1 1 3 3 0 0 0 0 0 0 0 3 1 0 3 3 2 2.7 50 46 Female 1 1 0 0 3 0 0 0 0 0 0 0 10 7 0 10 10 10 10 50 47 Female 1 0 0 1 1 1 0 0 1 0 0 0 4 3 12 5 1 1 2.3 52 48 Female 1 1 1 1 3 0 1 1 1 0 1 0 1 2 20 0 1 2 1 53 47 Female 1 1 0 0 3 0 0 0 1 0 0 0 7 6 0 8 2 5 5 53 48 Female 1 0 0 0 1 0 0 0 0 1 0 0 5 2 0 5 7 0 4 54 45 Female 1 1 1 1 3 0 0 0 1 0 1 0 4 1 2 6 4 0 3.3 54 46 Female 1 1 0 0 1 1 0 0 1 0 0 0 4 7 19 8 7 10 8.3 55 48 Female 0 0 0 0 1 1 0 0 0 0 0 0 4 7 10 2 5 1 2.7 55 50 Female 1 1 1 0 3 0 0 0 1 0 0 0 5 7 2 7 10 8 8.3 57 53 Female 0 1 0 0 3 0 0 0 0 0 0 0 6 3 0 4 10 9 7.7 57 53 Female 1 1 1 0 1 1 0 0 1 0 0 0 8 8 12 5 8 7 6.7 58 57 Female 0 0 0 0 1 1 0 0 1 0 0 0 5 5 9 8 5 8 7 58 56 Female 1 0 0 0 1 1 0 0 1 0 0 0 5 4 7 5 7 5 5.7 60 55 Female 1 1 1 1 3 0 0 0 0 0 0 0 1 2 0 9 1 3 4.3 60 50 Female 1 1 1 1 3 0 0 0 0 1 0 0 5 4 27 4 6 5 5 61 58 Female 1 1 0 0 3 1 0 0 0 0 0 0 7 4 10 6 8 9 7.7 61 59 Female 0 0 0 0 1 1 0 1 1 0 0 0 5 5 20 5 5 5 5 61 57 Female 1 1 0 0 1 1 0 0 0 0 0 0 5 5 7 5 3 5 4.3 63 59 Female 0 0 0 0 0 1 0 0 1 0 0 0 9 6 34 10 8 8 8.7 64 61 Female 1 0 0 0 1 1 0 0 0 0 0 0 8 6 10 5 9 9 7.7 65 54 Female 1 1 1 0 3 0 0 1 0 0 0 0 3 2 6 5 0 0 1.7 66 65 Male 1 0 0 0 1 1 0 0 1 0 0 0 10 7 7 6 10 10 8.7 67 64 Male 0 0 0 0 1 1 0 0 1 0 0 0 5 3 12 6 5 2 4.3 69 64 Female 1 0 0 0 3 0 0 0 1 1 1 1 9 7 19 9 7 10 8.7 69 66 Male 0 0 0 0 1 1 0 0 1 0 0 0 3 7 7 4 7 2 4.3 70 66 Male 1 0 0 0 1 1 0 0 1 0 0 0 5 3 18 0 5 5 3.3 71 67 Male 1 0 0 0 1 1 0 0 0 0 0 0 1 1 7 2 0 0 0.7 71 68 Male 1 0 0 0 1 1 0 0 1 0 0 0 3 3 12 2 4 3 3 71 70 Male 1 0 0 0 0 1 0 0 1 0 0 0 6 7 14 5 6 6 5.7 73 70 Male 0 0 0 0 1 1 0 0 1 0 0 0 6 5 7 5 6 5 5.3 75 73 Female 1 1 1 1 1 1 0 0 1 0 0 0 4 3 7 6 6 3 5 75 74 Female 0 0 0 0 1 1 0 0 1 0 0 0 7 5 7 5 7 9 7 77 73 Female 1 0 0 0 1 1 0 0 1 0 1 0 5 18 2 3 3 3.2 83 79 Female 1 0 0 0 1 1 0 0 1 0 0 0 9 6 9 0 5 7 4 ANA: antinuclear antibody, SSA: Sjogren’s syndrome A antibody, SSB: Sjogren’s syndrome B antibody, RF: rheumatoid factor, PNS: peripheral nervous system, CNS: central nervous system, PGA: patient global assessment, PhGA: physician global assessment, ESSDAI: EULAR Sjogren’s syndrome disease activity score, ESSPRI: EULAR Sjogren’s syndrome patient reported index
